Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the uncontrolled proliferation of immature lymphocytes. It is the most common childhood leukemia, though it also affects patients in adulthood, representing about 20% of adult leukemias. The goal of treatment in ALL is to reach complete remission and remove residual disease, ultimately to reduce the risk of relapse and improve transplant outcomes. With high rates of remission in the first-line setting, targeted agents and immunotherapies are being employed to improve outcomes for patients who relapse, providing a unique opportunity for novel therapies to impact the treatment landscape.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in ALL to help guide strategic and tactical commercial development decisions for market participants.